<code id='A4E3859B04'></code><style id='A4E3859B04'></style>

<acronym id='A4E3859B04'></acronym>

<center id='A4E3859B04'><center id='A4E3859B04'><tfoot id='A4E3859B04'></tfoot></center><abbr id='A4E3859B04'><dir id='A4E3859B04'><tfoot id='A4E3859B04'></tfoot><noframes id='A4E3859B04'>

<optgroup id='A4E3859B04'><strike id='A4E3859B04'><sup id='A4E3859B04'></sup></strike><code id='A4E3859B04'></code></optgroup>

<b id='A4E3859B04'><label id='A4E3859B04'><select id='A4E3859B04'><dt id='A4E3859B04'><span id='A4E3859B04'></span></dt></select></label></b><u id='A4E3859B04'></u>

~~<i id='A4E3859B04'><strike id='A4E3859B04'><tt id='A4E3859B04'><pre id='A4E3859B04'></pre></tt></strike></i>~~

Home» Wikipedia» entertainment

entertainment

entertainment

author：comprehensive 2025-10-06 16:54:47 Page View：8337

Adobe

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

advertisement

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： NIH director takes cautious approach to Biden drug pricing priority
Next article： Medical leaders decry Supreme Court decision on affirmative action

focus

Affirmative action in medical school literally saved lives

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

MollyFerguson/STATHello!SometakesandthoughtsonGilead’sTrodelvytroubles,ElevationOncology’ssurprising

Heart attack and stroke risk calculators need revising

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Beware reading your test results before your doctor does

AdobeNotsolongago,afatherbrokedownintearswithmeoverZoom—tearsofrelief.Whenthisfatherhadreceivedtestr

read more